- Home
- VTYX vs OCCI Comparison
VTYX vs OCCI Comparison
Compare VTYX & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- OCCI
- Stock Information
- Founded
- VTYX 2018
- OCCI N/A
- Country
- VTYX United States
- OCCI United States
- Employees
- VTYX N/A
- OCCI N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- VTYX Health Care
- OCCI Finance
- Exchange
- VTYX Nasdaq
- OCCI Nasdaq
- Market Cap
- VTYX 154.9M
- OCCI 135.3M
- IPO Year
- VTYX 2021
- OCCI N/A
- Fundamental
- Price
- VTYX $10.38
- OCCI $4.80
- Analyst Decision
- VTYX Strong Buy
- OCCI
- Analyst Count
- VTYX 5
- OCCI 0
- Target Price
- VTYX $14.60
- OCCI N/A
- AVG Volume (30 Days)
- VTYX 2.5M
- OCCI 115.8K
- Earning Date
- VTYX 11-06-2025
- OCCI 12-11-2023
- Dividend Yield
- VTYX N/A
- OCCI 24.32%
- EPS Growth
- VTYX N/A
- OCCI N/A
- EPS
- VTYX N/A
- OCCI N/A
- Revenue
- VTYX N/A
- OCCI N/A
- Revenue This Year
- VTYX N/A
- OCCI N/A
- Revenue Next Year
- VTYX N/A
- OCCI $10.19
- P/E Ratio
- VTYX N/A
- OCCI N/A
- Revenue Growth
- VTYX N/A
- OCCI N/A
- 52 Week Low
- VTYX $0.78
- OCCI $5.47
- 52 Week High
- VTYX $10.47
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- VTYX 74.09
- OCCI 50.26
- Support Level
- VTYX $8.90
- OCCI $4.31
- Resistance Level
- VTYX $10.02
- OCCI $4.62
- Average True Range (ATR)
- VTYX 0.78
- OCCI 0.16
- MACD
- VTYX -0.10
- OCCI 0.02
- Stochastic Oscillator
- VTYX 94.86
- OCCI 72.86
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.